158 related articles for article (PubMed ID: 15676214)
1. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Balaian L; Ball ED
Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.
Balaian L; Ball ED
Leuk Res; 2004 Aug; 28(8):821-9. PubMed ID: 15203280
[TBL] [Abstract][Full Text] [Related]
4. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression.
Balaian L; Zhong RK; Ball ED
Exp Hematol; 2003 May; 31(5):363-71. PubMed ID: 12763134
[TBL] [Abstract][Full Text] [Related]
6. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells.
Konopleva M; Estrov Z; Zhao S; Andreeff M; Mehta K
J Immunol; 1998 Nov; 161(9):4702-8. PubMed ID: 9794400
[TBL] [Abstract][Full Text] [Related]
7. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
8. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
Simard P; Leroux JC
Int J Pharm; 2009 Nov; 381(2):86-96. PubMed ID: 19446624
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
Bae J; Martinson JA; Klingemann HG
Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
[TBL] [Abstract][Full Text] [Related]
10. A synergistic increase of apoptosis utilizing Fas antigen expression induced by low doses of anticancer drug.
Akiyama H; Ino T; Tokunaga E; Katsuda I; Ezaki K
Rinsho Byori; 2003 Aug; 51(8):733-9. PubMed ID: 13677932
[TBL] [Abstract][Full Text] [Related]
11. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
12. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
Stiff PJ; Schulz WC; Bishop M; Marks L
Blood; 1991 Jan; 77(2):355-62. PubMed ID: 1985700
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
Muranyi AL; Dedhar S; Hogge DE
Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
[TBL] [Abstract][Full Text] [Related]
15. Antibody-targeted therapy for myeloid leukemia.
Appelbaum FR
Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
[TBL] [Abstract][Full Text] [Related]
16. Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.
Yang GS; Wang C; Minkin S; Minden MD; McCulloch EA
J Cell Physiol; 1991 Jul; 148(1):60-7. PubMed ID: 1860896
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor.
Imai N; Miwa H; Shikami M; Suganuma K; Gotoh M; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Shitara K; Shibuya M; Nitta M
Leuk Res; 2009 Dec; 33(12):1650-7. PubMed ID: 19342098
[TBL] [Abstract][Full Text] [Related]
18. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
19. Mylotarg approved for patients with CD33+ acute myeloid leukemia.
Sorokin P
Clin J Oncol Nurs; 2000; 4(6):279-80. PubMed ID: 11899326
[TBL] [Abstract][Full Text] [Related]
20. Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells.
Pérez-Oliva AB; Martínez-Esparza M; Vicente-Fernández JJ; Corral-San Miguel R; García-Peñarrubia P; Hernández-Caselles T
Glycobiology; 2011 Jun; 21(6):757-70. PubMed ID: 21278227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]